A lthough regadenoson has nearly replaced other vasodilator stressors for single-photon emission computed tomography perfusion imaging, the benefits of regadenoson stress for positron emission tomography (PET) perfusion are less clearly established, particularly in the estimation of absolute stress flow with dynamic PET imaging. In the estimation of absolute flow with dynamic PET, the timing of...

BACKGROUND Regadenoson is a vasodilator stress agent that selectively activates the A2A receptor. Compared to adenosine, regadenoson is easier to administer and results in fewer side effects. Although extensively studied in patients undergoing nuclear perfusion imaging (MPI), its use for perfusion cardiovascular magnetic resonance (CMR) is not well described. The aim of this study was to determ...

The incidence of false-positive stress tests has been noted in women, especially on hormone replacement therapy. Current literature describes this phenomenon in treadmill and adenosine stress tests. The introduction of regadenoson as a vasodilator agent has been widely adopted owing to its potency and specificity. To our knowledge, false-positive stress test with regadenoson in a postmenopausal...

Methods Forty patients with normal coronaries/minimal stenosis on coronary CT angiography had also undergone vasodilator stress MR (regadenoson n=20, dipyridamole n=20). Seventeen healthy normal volunteers with Framingham score less than 1% underwent vasodilator stress testing with regadenoson and dipyridamole in two separate studies using a SSFP sequence. Stress imaging was done 70 seconds pos...

BACKGROUND Real-time myocardial contrast echocardiography permits the detection of myocardial perfusion abnormalities during stress echocardiography, which may improve the accuracy of the test in detecting coronary artery stenoses. We hypothesized that this technique could be used after a bolus injection of the selective A2A receptor agonist regadenoson to rapidly and safely detect coronary art...

AIMS Knowledge of adverse events associated with regadenoson perfusion cardiac magnetic resonance (CMR) and patient tolerability has implications for patient safety and staff training. We sought to assess the safety and tolerability of regadenoson stress CMR. MATERIALS AND METHODS A group of 728 consecutive patients (median age 58, 44% female) and 25 normal volunteers (median age 21, 24% fema...

OBJECTIVE MPI can provide valuable information in the investigation of patients with known or suspected coronary artery disease. The stress component of the studies can be conducted with regadenoson, which was approved for clinical use in Greece in 2016. We investigated the performance and safety profile of regadenoson MPI based on our 7 months institutional experience. PATIENTS AND METHODS W...

In recent years, regadenoson has increasingly penetrated the clinical market as a novel pharmacologic stress agent for myocardial perfusion imaging (MPI). Regadenoson has favourable features such as a rapid onset of vasodilation with sustained action, enabling injection as a slow bolus, and a preferable side-effect profile when compared with adenosine due to adenosine A2A receptor subtype selec...

BACKGROUND Adenosine receptor stress agents for myocardial perfusion imaging (MPI) may cause A(2B) and/or A(3) receptor-mediated bronchoconstriction, of particular concern to physicians testing patients with asthma or chronic obstructive pulmonary disease (COPD). METHODS A Phase 4, randomized, double-blind study (NCT00862641) assessed the safety of the selective A(2A) receptor agonist, regade...